Books and Book Chapters

    Metabolism of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) In A/J Mouse Lung and Effect of Cigarette Smoke Exposure on In Vivo Metabolism to Biological Reactive Intermediates

    Tricker, A. R.; Brown, B. G.; Doolittle, D. J.; Richter, E.
    Date published
    Jun 15, 2001
    DOI
    10.1007/978-1-4615-0667-6_67
    ISBN
    978-1-4613-5185-6
    Published in
    Biological Reactive Intermediates VI. Advances in Experimental Medicine and Biology
    Editors
    Dansette, P. M.; Snyder, R.; Delaforge, M.; Gibson, G. G.; Greim, H.; Jollow, D. J.; Monks, T. J.; Sipes, I. G.
    Link to publication
    Topic
    Summary

    It has been proposed that the tobacco-specific N-nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) may be involved in the causation of human lung cancer (Hecht and Hoffmann, 1988), but direct evidence for the involvement of NNK in human lung cancer is lacking (Hecht and Tricker, 1999). In the A/J mouse lung tumor model, a single intraperitoneal (i.p.) injection of 10 μmole [2.07 mg] NNK/mouse results in 7–12 lung tumors per mouse after 16 weeks (Hecht et al., 1989). The initial events in NNK-induced A/J mouse lung tumorigenesis are believed to be metabolism of NNK to biological reactive intermediates (BRI) with the potential to react (via methylation of DNA) to produce O6-methylguanine (O6MeG), GC→AT transitional mispairing, and subsequent activation of the K-ras proto-oncogene (Ronai et al., 1993). α-Hydroxylation of the methylene carbon atoms adjacent to the N-nitroso group in NNK and NNAL yields unstable BM which spontaneously decompose to methanediazohydroxide with the potential to react with DNA to produce 7-methylguanine (7-MeG), O4-methylthymidine (O4MeT) and O6MeG adducts. α-Hydroxylation of the NNK methyl group yields a BM with the potential to pyridyloxobutylate DNA, while α-methyl hydroxylation of NNAL is not known to result in DNA adduct formation. Other metabolic transformations represent detoxification pathways for NNK and NNAL.

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.